#CrPC

Cancer Heterogeneity and Plasticity

@chp-pivot.bsky.social

2 weeks ago

Graphical abstract illustrating ARSI-induced lineage plasticity in prostate cancer. Androgen receptor signaling inhibition promotes transition from prostate adenocarcinoma (PRAD) to aggressive CRPC variants with increased mesenchymal, basal, stem-like, and neural cell states, highlighting reversibility and tumor heterogeneity.

📘 CHP Archive Spotlight #05
Perspective (2024) | Jamroze, Liu & Tang
AR signaling inhibitors induce lineage plasticity in prostate cancer, promoting stem-like, mesenchymal & neural states driving CRPC & NEPC progression.
🔗 doi.org/10.47248/chp...
#LineagePlasticity #CRPC #CancerStemCells

Goffin Vincent Lab

@goffinlab.bsky.social

1 month ago

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy - EMBO Molecular Medicine A critical knowledge gap in prostate cancer research is understanding whether castration-tolerant progenitor-like cells that reside in treatment-naïve tumors play a direct role in therapy resistance a...

Pleased to share our recent open access publication in #EMBO Molecular Medicine showing that early eradication of #castration-tolerant #Club cells presents a promising therapeutic strategy to mitigate #prostatecancer progression towards #CRPC
👇
link.springer.com/article/10.1...

@d-and-d-world.bsky.social

1 month ago

VCU researchers win $1.8 million US DoD grant for cancer therapy The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.

VCU researchers awarded $1.8M DoD grant to develop a novel engineered NK cell therapy targeting incurable, advanced prostate cancer (CRPC).
#News #ProstateCancer #Immunotherapy #CRPC #CellTherapy #NKcells #IL24 #DoDgrant

Phalguni Deswal

@phalguniddw.bsky.social

1 month ago

VCU researchers win $1.8 million US DoD grant for cancer therapy The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.

VCU researchers awarded $1.8M DoD grant to develop a novel engineered NK cell therapy targeting incurable, advanced prostate cancer (CRPC).
#News #ProstateCancer #Immunotherapy #CRPC #CellTherapy #NKcells #IL24 #DoDgrant

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

2 months ago

Researchers develop a #PSMA‑targeted self‑assembling nano‑PROTAC that simultaneously degrades AR, AR‑V7, and HSP90 in #CRPC, overcoming resistance to AR inhibitors, achieving potent #antitumor activity with tumor‑specific accumulation.

#OpenAccess in #STTT: doi.org/10.1038/s413...

OncLive

@onclive.bsky.social

3 months ago

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC | OncLive Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC #oncology #pcsm #CRPC
www.onclive.com/view/venetoc...

Epigenome Technologies

@epigenometech.bsky.social

3 months ago

Epigenetics Update - The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer bit.ly/4a8C1cI

#Epigenetics #KMT2D #Cancer #CRPC

---
Discover the breakthrough at epigenometech.com

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

3 months ago

The LTFe–LTF #enhancerRNA axis is identified as a #ferroptosis-promoting #TumorSuppressor in #ProstateCancer, with AR signaling disrupting LTFe-mediated chromatin looping, and #enzalutamide + RSL3 suppresses #CRPC growth.

#OpenAccess in #STTT: doi.org/10.1038/s413...

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

4 months ago

As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

#GSK #oncology #Blenrep #ADC #antibodydrugconjugates #prostatecancercandidate #Syndivia #advancedcastrationresistantprostatecancer #CRPC #mCRPC #multiplemyeloma #multiplemyelomaADC #prostatecancer #B7H3targetedADC #Hansoh #osteosarcoma #ESMO #GeminiMabconjugationtechnology
zurl.co/8KpGz

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

4 months ago

Bayer's prostate cancer drug Nubeqa cleared for NHS use Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

#menshealth #NICErecommended #Bayer #prostatecancer #Nubeqa #darolutamide #Nubeqaregimen #hormonesensitiveprostatecancer #HSPC #androgendeprivationtherapy #ProstateCancerUK #advancedHSPC #ARANOTEtrial #castrationresistantprostatecancer #CRPC #mHSPC #NationalProstateCancerAudit #NPCA
zurl.co/dDIIm

Pablo Sanchis, PhD

@pblsanchis.bsky.social

7 months ago

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression - Oncogene Oncogene - PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression

Check out our work unveiling how the bone #TME drives Osteopontin expression in #metastatic prostate cancer and its association with resistance to AR signaling blockade #ARSI #CRPC

@oncodaily.bsky.social #Oncodaily @mdanderson.bsky.social @pcf-science.bsky.social www.nature.com/articles/s41...

OncLive

@onclive.bsky.social

8 months ago

FDA Grants Fast Track Designation to TRE-515 Plus Radioligand Therapy in PSMA+ mCRPC TRE-515 has received FDA fast track designation in combination with radioligand therapy for PSMA-positive mCRPC.

FDA Grants Fast Track Designation to TRE-515 Plus Radioligand Therapy in PSMA+ mCRPC #oncology #CRPC
www.onclive.com/view/fda-gra...

OncLive

@onclive.bsky.social

9 months ago

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
#CRPC #ProstateCancer #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/olapari...

Laurent Trastour

@laftrastour.bsky.social

10 months ago

#Justice : l’on parle du «plaider coupable» #CRPC pour les crimes, des peines minimum, mais pas des propositions pour la #Justice #Civile . Dont la #Déjudiciarisation.
En oubliant le problème essentiel : manque persistant de moyens et d’effectifs, malgré les efforts du prédécesseur de Darmanin.

@anokhashunya0.bsky.social

10 months ago

Core Legal Provision: Section 528, BNSS
▪️Replaces: Section 482, CrPC (1973).
▪️Essence: Grants High Courts inherent powers to:
▪️Prevent abuse of court processes.
▪️Secure the ends of justice.
Scope: Quash FIRs, or chargesheets that lack merit or are filed with ulterior motives. #BNSS #CrPC

Onco404

@onco404.bsky.social

10 months ago

✅ First AI model validated in #CRPC, bridging hormone-sensitive & resistant settings.

This digital pathology-based MMAI tool is prognostic and predictive in nmCRPC, potentially guiding treatment intensification by identifying high-risk patients most likely to benefit from apalutamide.

#Onco404 #AI

OncLive

@onclive.bsky.social

10 months ago

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC @fredhutch.bsky.social #oncology #CRPC
www.onclive.com/view/psma-pe...

Martin Schostak MD, PhD

@martin-schostak.bsky.social

1 year ago

🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.